Biotech

All Articles

Actinogen's cortisol blocker stops working period 2 depression research

.Actinogen Medical's cortisol blocker has actually missed the primary endpoint of a stage 2 research...

Bivictrix determines going personal only way to take ADC right into medical clinic

.Antibody-drug conjugates (ADCs) have been at the facility of several a billion-dollar biobuck licen...

TPG tops up funds to $580M for assets across lifestyle sciences

.Asset manager TPG, which has sustained biotechs such as Sionna Rehabs and Santa Ana Biography, has ...

Merck stops period 3 TIGIT test in lung cancer cells for impossibility

.Merck &amp Co.'s TIGIT plan has actually endured one more problem. Months after shuttering a period...

After a tough year, Exscientia folds up into Recursion

.After a year defined through pipeline cuts, the departure of its own CEO as well as layoffs, Exscie...

Cullinan, after $25M deal, restore bispecific to Port

.Cullinan Therapeutics was actually wowed enough with Harbour BioMed's bispecific immune activator t...

A deeper check out Fierce Biotech's Tough 15

.In this particular full week's incident of "The Top Line," we are actually diving right into Fierce...

Lilly experiences period 2 failure of tau-targeting med

.The confetti is actually still soaring from Eli Lilly's party commemorating the approval of Alzheim...

Biogen CMO Maha Radhakrishnan joins Sofinnova-- Chutes &amp Ladders

.Accept to today's Chutes &amp Ladders, our summary of notable leadership hirings, shootings as well...

Lykos will definitely inquire FDA to reassess its own decision complying with denial of MDMA treatment for post-traumatic stress disorder

.Observing an unsatisfactory presenting for Lykos Therapies' MDMA candidate for post-traumatic stres...